LobbyingN Brereton Medical Technologies lobbying by quarter
N Brereton Medical Technologies's latest lobbying report covers Q2 2026, at $20K. The four quarters Q4 2025–Q3 2026 total $45K. Its first report covers Q2 2025; the issues it reports most are Alcohol & Drug Abuse and Health Issues.
N Brereton Medical Technologies
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $45K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q2 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q2 2025 | $15K | 1 |
| Q3 2025 | $15K | 1 |
| Q4 2025 | $15K | 1 |
| Q1 2026 | $10K | 2 |
| Q2 2026 | $20K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Alcohol and drug abuse$55K · 5 reports
- Health issues$20K · 1 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Health & Human Services, Dept of (HHS)6 reports
- HOUSE OF REPRESENTATIVES5 reports
- SENATE5 reports
- Natl Institutes of Health (NIH)4 reports
- Food & Drug Administration (FDA)2 reports
- Veterans Affairs, Dept of (VA)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| The Consilio Group | $45K | 4 quarters |
| Ervin Graves Strategy Group | $30K | 2 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| BRANDON KIRBY | Director of Government Relations | Q1 2026 |
| OLIVER MEISSNER | CEO | Q1 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/19for Q2 | Ervin Graves Strategy Group | $20K |
| 04/17for Q1 | Ervin Graves Strategy Group | $10K |
| 04/15for Q1 | The Consilio Group | Under $5,000 |
| 04/09for Q4 2025 | The Consilio Group | $15K |
| 04/01for Q1 | Ervin Graves Strategy Group | Under $5,000 |
| 25/10/20for Q3 2025 | The Consilio Group | $15K |
| 25/07/23for Q2 2025 | The Consilio Group | $15K |
| 25/07/22for Q2 2025 | The Consilio Group | Under $5,000 |